2025--12-31 false 0001850902 Q3 0001850902 us-gaap:SalesRevenueNetMember tkno:DistributorCustomerAMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001850902 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001850902 tkno:DirectSupplierAMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001850902 us-gaap:VehiclesMember 2024-12-31 0001850902 us-gaap:NonUsMember 2025-01-01 2025-09-30 0001850902 us-gaap:TradeNamesMember 2025-09-30 0001850902 tkno:ClinicalSolutionsMember 2024-07-01 2024-09-30 0001850902 tkno:OtherProductMember 2024-01-01 2024-09-30 0001850902 tkno:ClinicalSolutionsMember 2025-01-01 2025-09-30 0001850902 us-gaap:AccountsPayableMember tkno:DistributorCustomerAMember us-gaap:CustomerConcentrationRiskMember 2024-12-31 0001850902 tkno:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember 2025-01-01 2025-09-30 0001850902 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001850902 tkno:EmployeeStockOptionPlansMember 2024-01-01 2024-09-30 0001850902 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001850902 2024-06-06 2024-06-06 0001850902 tkno:LabEssentialsMember 2024-07-01 2024-09-30 0001850902 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001850902 us-gaap:RetainedEarningsMember 2024-06-30 0001850902 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001850902 tkno:OtherProductMember 2025-01-01 2025-09-30 0001850902 us-gaap:RetainedEarningsMember 2025-09-30 0001850902 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001850902 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001850902 us-gaap:MachineryAndEquipmentMember 2024-12-31 0001850902 country:US 2025-01-01 2025-09-30 0001850902 tkno:EmployeeStockOptionPlansMember 2025-01-01 2025-09-30 0001850902 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001850902 2025-07-31 2025-07-31 0001850902 tkno:SecondAmendedAndRestatedCreditAgreementMember tkno:SofrFloorMember 2025-03-03 2025-03-03 0001850902 tkno:ReductionInForceMember 2024-01-11 2024-01-11 0001850902 tkno:DirectSupplierCMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001850902 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001850902 tkno:EmployeeShareBasedAwardsMember 2024-01-01 2024-09-30 0001850902 us-gaap:CommonStockMember 2025-06-30 0001850902 tkno:DirectSupplierCMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001850902 us-gaap:VehiclesMember 2025-09-30 0001850902 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 2024-12-31 0001850902 2025-03-03 2025-03-03 0001850902 2025-11-05 0001850902 tkno:TheFacilityMember 2025-03-03 0001850902 2025-09-30 0001850902 tkno:DirectSupplierAMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001850902 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001850902 us-gaap:RetainedEarningsMember 2023-12-31 0001850902 tkno:AmendedRevolvingLoanMember srt:MinimumMember 2025-03-03 0001850902 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001850902 tkno:DirectSupplierCMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001850902 us-gaap:NonUsMember 2024-01-01 2024-09-30 0001850902 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001850902 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001850902 tkno:SeniorSecuredTermLoanMember 2025-03-03 0001850902 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001850902 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001850902 2025-03-03 0001850902 tkno:EmployeeShareBasedAwardsMember 2025-07-01 2025-09-30 0001850902 us-gaap:CommonStockMember 2024-06-30 0001850902 2023-12-31 0001850902 tkno:DirectSupplierBMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001850902 us-gaap:GeneralAndAdministrativeExpenseMember 2025-07-01 2025-09-30 0001850902 us-gaap:SalesRevenueNetMember tkno:DistributorCustomerAMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001850902 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001850902 us-gaap:RetainedEarningsMember 2024-12-31 0001850902 2024-06-30 0001850902 2024-12-31 0001850902 tkno:ClinicalSolutionsMember 2024-01-01 2024-09-30 0001850902 us-gaap:CommonStockMember 2025-09-30 0001850902 us-gaap:CommonStockMember 2024-12-31 0001850902 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001850902 country:US 2025-07-01 2025-09-30 0001850902 tkno:OtherProductMember 2024-07-01 2024-09-30 0001850902 us-gaap:RetainedEarningsMember 2025-06-30 0001850902 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001850902 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001850902 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001850902 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001850902 tkno:DirectSupplierCMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001850902 us-gaap:SalesRevenueNetMember tkno:DistributorCustomerAMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001850902 tkno:OfficeFurnitureAndEquipmentMember 2024-12-31 0001850902 us-gaap:EmployeeStockOptionMember 2024-12-31 0001850902 tkno:SecondAmendedAndRestatedCreditAgreementMember tkno:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2025-03-03 2025-03-03 0001850902 us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001850902 tkno:LabEssentialsMember 2025-07-01 2025-09-30 0001850902 2025-07-01 2025-09-30 0001850902 us-gaap:CustomerRelationshipsMember 2025-09-30 0001850902 tkno:EmployeeShareBasedAwardsMember 2024-07-01 2024-09-30 0001850902 tkno:RepricingOfOutstandingAndUnexercisedOptionsMember 2024-03-14 2024-03-14 0001850902 us-gaap:LeaseholdImprovementsMember 2025-09-30 0001850902 us-gaap:CostOfSalesMember 2025-01-01 2025-09-30 0001850902 us-gaap:RetainedEarningsMember 2024-09-30 0001850902 tkno:EmployeeStockOptionPlansMember 2024-07-01 2024-09-30 0001850902 tkno:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember 2024-07-01 2024-09-30 0001850902 tkno:LabEssentialsMember 2024-01-01 2024-09-30 0001850902 tkno:DistributorCustomerAMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001850902 2025-01-01 2025-09-30 0001850902 tkno:SecondAmendedAndRestatedCreditAgreementMember srt:MinimumMember 2025-01-01 2025-12-31 0001850902 tkno:ClinicalSolutionsMember 2025-07-01 2025-09-30 0001850902 tkno:SecondAmendedAndRestatedCreditAgreementMember tkno:RevolverMember 2025-03-03 0001850902 2024-07-01 2024-09-30 0001850902 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001850902 us-gaap:NonUsMember 2024-07-01 2024-09-30 0001850902 tkno:DistributorCustomerAMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001850902 tkno:AmendedCreditAgreementMember 2025-03-03 2025-03-03 0001850902 srt:MaximumMember 2025-09-30 0001850902 us-gaap:SellingAndMarketingExpenseMember 2025-01-01 2025-09-30 0001850902 2025-06-30 0001850902 2024-01-01 2024-09-30 0001850902 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001850902 country:US 2024-07-01 2024-09-30 0001850902 us-gaap:WarrantMember 2025-07-01 2025-09-30 0001850902 us-gaap:NonUsMember 2025-07-01 2025-09-30 0001850902 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0001850902 tkno:LabEssentialsMember 2025-01-01 2025-09-30 0001850902 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001850902 us-gaap:EmployeeStockOptionMember 2025-09-30 0001850902 us-gaap:TradeNamesMember 2024-12-31 0001850902 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001850902 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001850902 us-gaap:ResearchAndDevelopmentExpenseMember 2025-07-01 2025-09-30 0001850902 tkno:OtherProductMember 2025-07-01 2025-09-30 0001850902 tkno:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember 2025-07-01 2025-09-30 0001850902 tkno:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001850902 tkno:DistributorCustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-09-30 0001850902 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001850902 tkno:EmployeeStockOptionPlansMember 2025-07-01 2025-09-30 0001850902 srt:MinimumMember 2025-09-30 0001850902 tkno:OfficeFurnitureAndEquipmentMember 2025-09-30 0001850902 tkno:SecondAmendedAndRestatedCreditAgreementMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2025-03-03 2025-03-03 0001850902 tkno:SecondAmendedAndRestatedCreditAgreementMember 2025-03-03 2025-03-03 0001850902 us-gaap:AccountsPayableMember tkno:DistributorCustomerAMember us-gaap:CustomerConcentrationRiskMember 2025-09-30 0001850902 2024-09-30 0001850902 tkno:TwoThousandAndTwentyOneEquityIncentivePlanMember 2025-01-01 2025-09-30 0001850902 tkno:TwoThousandAndTwentyOneEquityIncentivePlanMember tkno:EmployeeMember 2025-01-01 2025-09-30 0001850902 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001850902 us-gaap:SalesRevenueNetMember tkno:DistributorCustomerAMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001850902 tkno:DistributorCustomerAMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001850902 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001850902 tkno:SecondAmendedAndRestatedCreditAgreementMember 2025-03-03 0001850902 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001850902 country:US 2024-01-01 2024-09-30 0001850902 us-gaap:EmployeeStockOptionMember 2024-12-31 2024-12-31 0001850902 us-gaap:CustomerRelationshipsMember 2024-12-31 0001850902 tkno:DistributorCustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-12-31 0001850902 tkno:RepricingOfOutstandingAndUnexercisedOptionsMember 2024-03-14 0001850902 us-gaap:RestrictedStockUnitsRSUMember 2025-09-30 0001850902 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001850902 us-gaap:CommonStockMember 2023-12-31 0001850902 us-gaap:CommonStockMember 2024-09-30 0001850902 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-09-30 0001850902 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-09-30 0001850902 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001850902 us-gaap:CostOfSalesMember 2025-07-01 2025-09-30 0001850902 us-gaap:MachineryAndEquipmentMember 2025-09-30 0001850902 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001850902 tkno:DistributorCustomerAMember tkno:InventoryPurchasesMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001850902 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001850902 tkno:SecondAmendedAndRestatedCreditAgreementMember srt:MinimumMember 2025-03-03 0001850902 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001850902 us-gaap:SellingAndMarketingExpenseMember 2025-07-01 2025-09-30 0001850902 tkno:EmployeeShareBasedAwardsMember 2025-01-01 2025-09-30 0001850902 us-gaap:CommonStockMember 2025-01-01 2025-09-30 xbrli:pure iso4217:USD xbrli:shares xbrli:shares tkno:Positions iso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-40538

ALPHA TEKNOVA, INC.

(Exact name of registrant as specified in its charter)

Delaware | 94-3368109
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)
2451 Bert Dr. Hollister, CA | 95023
(Address of principal executive offices) | (Zip Code)

(831) 637-1100

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $0.00001 per share |  | TKNO |  | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer |  | ☐ |  | Accelerated filer |  | ☐
Non-accelerated filer |  | ☒ |  | Smaller reporting company |  | ☒
Emerging growth company |  | ☒ |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 5, 2025, the registrant had 53,529,174 shares of common stock, $0.00001 par value per share, outstanding.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements relating to our financial condition, results of operations, plans, objectives, future performance and business, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “would,” “potential,” “likely,” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q may include, but are not limited to, statements about:

•
general economic, market or business conditions as well as those in the specific industry and markets in which our business operates which may impact customer demand for our products;
•
our ability to meet our publicly announced guidance or other expectations about our business;
•
our future financial performance, including our revenue, costs of revenue, and operating expenses;
•
our ability to grow profitability;
•
our ability to expand our operations and increase capacity;
•
our anticipated uses of cash in the short and long terms and the sufficiency of our sources of liquidity;
•
our ability to defend against claims and mitigate adverse results from any legal proceedings against us and the merits of any claims or suits against us;
•
our recent history of losses and our ability to continue as a going concern;
•
our ability to limit our accounts receivable and credit risk exposure;
•
our future investments, if any, in additional facilities to facilitate our expected growth;
•
our future uses of capital to pursue potential acquisitions, if any, that further or accelerate our strategy;
•
our future use of equity or debt financings to execute our business strategy;
•
our ability to take advantage of certain exemptions from various reporting requirements generally applicable to public companies;
•
our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the JOBS Act);
•
the impact of any pandemic, epidemic, or outbreak of infectious disease (including COVID-19), natural disasters, geopolitical unrest, war (including in Ukraine and the Israeli-Hamas war), terrorism, public health issues or other catastrophic events may have on our business and our ability to actively manage our response to these types of events;
•
our future adoption of critical accounting policies and estimates;
•
our ability to increase the scale and capacity of, or otherwise effectively adjust, our manufacturing processes and systems in response to market demands;
•
the impact of increased competition from additional companies entering the market and the availability of more advanced technologies in the market;
•
our ability to hire and retain key personnel;
•
our ability to obtain capital on favorable terms, or at all;
•
our ability to generate future revenue growth in market segments such as molecular diagnostics, synthetic biology, and emerging therapeutic modalities;
•
the impact of increased costs on our operations, including materials, labor, and general inflation;
•
our ability to use cash on hand to meet current and future financial obligations, including funding our operations, debt service requirements, and capital expenditures;
•
the enforceability of our exclusive forum provisions in our amended and restated certificate of incorporation;
•
our customers’ sensitivity to product nonconformances, defects, and errors;

2

•
the availability of exemption of our products from compliance with the U.S. Food, Drug and Cosmetic Act (FDCA);
•
our ability to secure and maintain a stable supply of raw materials in the future;
•
our ability to maintain a corporate culture that contributes to our success;
•
the marketability of our products across a wide range of markets and the probability of success or revenue opportunity in our target markets;
•
regulatory developments in the United States (U.S.) and other countries;
•
the impact of revenue recognition rules and other factors on our financial results;
•
our ability to obtain, maintain, and enforce intellectual property protection for our current and future products, including our ability to protect our trade secrets, trademarks, and trade names; and
•
the ongoing expenses associated with being a public company.

We caution you that the foregoing list may not contain all the forward-looking statements made in this Quarterly Report on Form 10-Q.

We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, assumptions, and other factors described in the section titled “Risk Factors” in Part I, Item 1A, of our Annual Report on Form 10-K filed with the SEC on March 7, 2025 (the 2024 Annual Report on Form 10-K) and elsewhere in this Quarterly Report on Form 10-Q. These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional factors that could adversely impact our business and financial performance. Furthermore, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. We cannot assure you that the results, events, and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions and are based upon information available to us as of the date of this Quarterly Report on Form 10-Q. Although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to rely upon these statements unduly.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which such statements are made. We undertake no obligation to update any forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform such statements to actual results or revised expectations, except as required by law.

Unless the context otherwise requires, the terms “Teknova,” the “Company,” “we,” “us,” and “our” in this Quarterly Report on Form 10-Q refer to Alpha Teknova, Inc.

3

ALPHA TEKNOVA, INC.

Form 10-Q for the Quarter Ended September 30, 2025

INDEX

|  |  |  | Page
PART I. |  | FINANCIAL INFORMATION |  |
Item 1. |  | Condensed Financial Statements (Unaudited) |  | 5
|  | Condensed Statements of Operations (Unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 |  | 5
|  | Condensed Balance Sheets (Unaudited) at September 30, 2025 and December 31, 2024 |  | 6
|  | Condensed Statements of Stockholders’ Equity (Unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 |  | 7
|  | Condensed Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2025 and 2024 |  | 9
|  | Notes to Unaudited Condensed Financial Statements |  | 10
Item 2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 20
Item 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  | 29
Item 4. |  | Controls and Procedures |  | 29
PART II. |  | OTHER INFORMATION |  | 30
Item 1. |  | Legal Proceedings |  | 30
Item 1A. |  | Risk Factors |  | 31
Item 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 32
Item 3. |  | Defaults Upon Senior Securities |  | 32
Item 4. |  | Mine Safety Disclosures |  | 32
Item 5. |  | Other Information |  | 32
Item 6. |  | Exhibits |  | 32
Signatures |  |  |  | 34

4

PART I – FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

ALPHA TEKNOVA, INC.

Condensed Statements of Operatio ns

(Unaudited)

(in thousands, except share and per share data)

|  | For the Three Months Ended September 30, |  |  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Revenue |  | $ | 10,454 |  |  | $ | 9,576 |  |  | $ | 30,536 |  |  | $ | 28,480 |
Cost of sales |  |  | 7,248 |  |  |  | 9,486 |  |  |  | 20,339 |  |  |  | 23,377 |
Gross profit |  |  | 3,206 |  |  |  | 90 |  |  |  | 10,197 |  |  |  | 5,103 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 542 |  |  |  | 627 |  |  |  | 1,675 |  |  |  | 2,165 |
Sales and marketing |  |  | 1,747 |  |  |  | 1,640 |  |  |  | 4,960 |  |  |  | 4,763 |
General and administrative |  |  | 4,647 |  |  |  | 4,968 |  |  |  | 15,068 |  |  |  | 17,832 |
Amortization of intangible assets |  |  | 287 |  |  |  | 287 |  |  |  | 861 |  |  |  | 861 |
Total operating expenses |  |  | 7,223 |  |  |  | 7,522 |  |  |  | 22,564 |  |  |  | 25,621 |
Loss from operations |  |  | (4,017 | ) |  |  | (7,432 | ) |  |  | (12,367 | ) |  |  | (20,518 | )
Other expenses, net |  |  |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  | (190 | ) |  |  | (141 | ) |  |  | (499 | ) |  |  | (558 | )
Other adjustment to loan exit fee |  |  | — |  |  |  | — |  |  |  | 485 |  |  |  | — |
Total other expenses, net |  |  | (190 | ) |  |  | (141 | ) |  |  | (14 | ) |  |  | (558 | )
Loss before income taxes |  |  | (4,207 | ) |  |  | (7,573 | ) |  |  | (12,381 | ) |  |  | (21,076 | )
Provision for (benefit from) income taxes |  |  | 79 |  |  |  | (8 | ) |  |  | 120 |  |  |  | (50 | )
Net loss |  | $ | (4,286 | ) |  | $ | (7,565 | ) |  | $ | (12,501 | ) |  | $ | (21,026 | )
Net loss per share—basic and diluted |  | $ | (0.08 | ) |  | $ | (0.15 | ) |  | $ | (0.23 | ) |  | $ | (0.47 | )
Weighted average shares used in computing net loss per share—basic and diluted |  |  | 53,516,986 |  |  |  | 51,821,395 |  |  |  | 53,462,768 |  |  |  | 44,520,132 |

The accompanying notes are an integral part of these condensed financial statements.

5

ALPHA TEKNOVA, INC.

Condensed B alance Sheets

(Unaudited)

(in thousands, except share and per share data)

|  | As of September 30, 2025 |  |  | As of December 31, 2024 |
ASSETS |  |  |  |  |  |
Current assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 3,204 |  |  | $ | 3,708 |
Short-term investments, held -to-maturity |  |  | 18,912 |  |  |  | 26,688 |
Accounts receivable, net of allowance for credit losses of $48 and $83 as of September 30, 2025 and December 31, 2024, respectively |  |  | 5,135 |  |  |  | 4,312 |
Inventories, net |  |  | 6,914 |  |  |  | 6,801 |
Prepaid expenses and other current assets |  |  | 2,398 |  |  |  | 1,267 |
Total current assets |  |  | 36,563 |  |  |  | 42,776 |
Property, plant, and equipment, net |  |  | 42,623 |  |  |  | 45,753 |
Operating right-of-use lease assets |  |  | 14,894 |  |  |  | 15,767 |
Intangible assets, net |  |  | 12,230 |  |  |  | 13,091 |
Other non-current assets |  |  | 1,315 |  |  |  | 1,382 |
Total assets |  | $ | 107,625 |  |  | $ | 118,769 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |
Accounts payable |  | $ | 1,084 |  |  | $ | 825 |
Accrued liabilities |  |  | 3,966 |  |  |  | 4,541 |
Current portion of operating lease liabilities |  |  | 1,886 |  |  |  | 1,800 |
Current portion of long-term debt |  |  | — |  |  |  | 4,045 |
Total current liabilities |  |  | 6,936 |  |  |  | 11,211 |
Deferred tax liabilities |  |  | 946 |  |  |  | 827 |
Other accrued liabilities |  |  | — |  |  |  | 10 |
Long-term debt, net |  |  | 13,076 |  |  |  | 9,443 |
Long-term operating lease liabilities |  |  | 14,017 |  |  |  | 14,884 |
Total liabilities |  |  | 34,975 |  |  |  | 36,375 |
Commitments and contingencies (Note 16) |  |  |  |  |  |
Stockholders’ equity: |  |  |  |  |  |
Preferred stock, $0.00001 par value, 10,000,000 shares authorized at September 30, 2025 and December 31, 2024, respectively, zero shares issued and outstanding at September 30, 2025 and December 31, 2024 |  |  | — |  |  |  | — |
Common stock, $0.00001 par value, 490,000,000 shares authorized at September 30, 2025 and December 31, 2024, 53,524,460 and 53,409,727 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively |  |  | 1 |  |  |  | 1 |
Additional paid-in capital |  |  | 203,681 |  |  |  | 200,924 |
Accumulated deficit |  |  | (131,032 | ) |  |  | (118,531 | )
Total stockholders’ equity |  |  | 72,650 |  |  |  | 82,394 |
Total liabilities and stockholders’ equity |  | $ | 107,625 |  |  | $ | 118,769 |

The accompanying notes are an integral part of these condensed financial statements.

6

ALPHA TEKNOVA, INC.

Condensed Statements of Stockholders’ Equity

(in thousands, except share data)

(Unaudited)

|  | Common Stock |  |  | Additional Paid-in |  |  | Accumulated |  |  | Stockholders’ |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Equity |
Balance at July 1, 2025 |  |  | 53,514,288 |  |  | $ | 1 |  |  | $ | 202,802 |  |  | $ | (126,746 | ) |  | $ | 76,057 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 850 |  |  |  | — |  |  |  | 850 |
Issuance of common stock upon exercise of stock options |  |  | 10,172 |  |  |  | — |  |  |  | 29 |  |  |  | — |  |  |  | 29 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,286 | ) |  |  | (4,286 | )
Balance at September 30, 2025 |  |  | 53,524,460 |  |  | $ | 1 |  |  | $ | 203,681 |  |  | $ | (131,032 | ) |  | $ | 72,650 |

|  | Common Stock |  |  | Additional Paid-in |  |  | Accumulated |  |  | Stockholders’ |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Equity |
Balance at July 1, 2024 |  |  | 40,915,331 |  |  | $ | — |  |  | $ | 184,175 |  |  | $ | (105,247 | ) |  | $ | 78,928 |
Equity financing, net of issuance costs |  |  | 12,385,883 |  |  |  | 1 |  |  |  | 15,140 |  |  |  | — |  |  |  | 15,141 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 760 |  |  |  | — |  |  |  | 760 |
Issuance of common stock upon exercise of stock options |  |  | 1,779 |  |  |  | — |  |  |  | 4 |  |  |  | — |  |  |  | 4 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (7,565 | ) |  |  | (7,565 | )
Balance at September 30, 2024 |  |  | 53,302,993 |  |  | $ | 1 |  |  | $ | 200,079 |  |  | $ | (112,812 | ) |  | $ | 87,268 |

The accompanying notes are an integral part of these condensed financial statements.

7

ALPHA TEKNOVA, INC.

Condensed Statements of Stockholders’ Equity

(in thousands, except share data)

(Unaudited)

|  | Common Stock |  |  | Additional Paid-in |  |  | Accumulated |  |  | Stockholders’ |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Equity |
Balance at January 1, 2025 |  |  | 53,409,727 |  |  | $ | 1 |  |  | $ | 200,924 |  |  | $ | (118,531 | ) |  | $ | 82,394 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 2,652 |  |  |  | — |  |  |  | 2,652 |
Issuance of common stock upon exercise of stock options |  |  | 20,677 |  |  |  | — |  |  |  | 49 |  |  |  | — |  |  |  | 49 |
Vesting of restricted stock units |  |  | 82,538 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Issuance of common stock under employee stock purchase plan |  |  | 11,518 |  |  |  | — |  |  |  | 56 |  |  |  | — |  |  |  | 56 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (12,501 | ) |  |  | (12,501 | )
Balance at September 30, 2025 |  |  | 53,524,460 |  |  | $ | 1 |  |  | $ | 203,681 |  |  | $ | (131,032 | ) |  | $ | 72,650 |

|  | Common Stock |  |  | Additional Paid-in |  |  | Accumulated |  |  | Stockholders’ |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Equity |
Balance at January 1, 2024 |  |  | 40,793,848 |  |  | $ | — |  |  | $ | 181,822 |  |  | $ | (91,786 | ) |  | $ | 90,036 |
Equity financing, net of issuance costs |  |  | 12,385,883 |  |  |  | 1 |  |  |  | 15,140 |  |  |  | — |  |  |  | 15,141 |
Issuance of common stock warrants |  |  | — |  |  |  | — |  |  |  | 132 |  |  |  | — |  |  |  | 132 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 2,900 |  |  |  | — |  |  |  | 2,900 |
Issuance of common stock upon exercise of stock options |  |  | 1,779 |  |  |  | — |  |  |  | 4 |  |  |  | — |  |  |  | 4 |
Vesting of restricted stock units |  |  | 67,169 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Issuance of common stock under employee stock purchase plan |  |  | 54,314 |  |  |  | — |  |  |  | 81 |  |  |  | — |  |  |  | 81 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (21,026 | ) |  |  | (21,026 | )
Balance at September 30, 2024 |  |  | 53,302,993 |  |  | $ | 1 |  |  | $ | 200,079 |  |  | $ | (112,812 | ) |  | $ | 87,268 |

The accompanying notes are an integral part of these condensed financial statements.

8

ALPHA TEKNOVA, INC.

Condensed Statem ents of Cash Flows

(Unaudited)

(in thousands)

|  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |
Operating activities: |  |  |  |  |  |
Net loss |  | $ | (12,501 | ) |  | $ | (21,026 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |
Bad debt expense |  |  | 71 |  |  |  | 61 |
Inventory reserve |  |  | 1,657 |  |  |  | 4,235 |
Depreciation and amortization |  |  | 4,761 |  |  |  | 4,933 |
Stock-based compensation |  |  | 2,652 |  |  |  | 2,900 |
Deferred taxes |  |  | 119 |  |  |  | (52 | )
Accrued interest income on short-term investments |  |  | (8 | ) |  |  | (118 | )
Amortization of discount on short-term investments |  |  | (508 | ) |  |  | — |
Amortization of debt financing costs |  |  | 173 |  |  |  | 291 |
Other adjustment to loan exit fee |  |  | (485 | ) |  |  | — |
Non-cash lease expense |  |  | 92 |  |  |  | 140 |
Loss on disposal of property, plant, and equipment |  |  | 19 |  |  |  | 49 |
Changes in operating assets and liabilities: |  |  |  |  |  |
Accounts receivable |  |  | (894 | ) |  |  | (718 | )
Inventories |  |  | (1,770 | ) |  |  | (315 | )
Prepaid expenses and other current assets |  |  | (1,464 | ) |  |  | (943 | )
Other non-current assets |  |  | 67 |  |  |  | 334 |
Accounts payable |  |  | 244 |  |  |  | (430 | )
Accrued liabilities |  |  | (399 | ) |  |  | (724 | )
Other |  |  | (10 | ) |  |  | (72 | )
Cash used in operating activities |  |  | (8,184 | ) |  |  | (11,455 | )
Investing activities: |  |  |  |  |  |
Purchases of short-term investments |  |  | (13,708 | ) |  |  | (25,428 | )
Maturities of short-term investments |  |  | 22,000 |  |  |  | — |
Proceeds from sale of property, plant, and equipment |  |  | — |  |  |  | 125 |
Purchases of property, plant, and equipment |  |  | (800 | ) |  |  | (558 | )
Cash provided by (used in) investing activities |  |  | 7,492 |  |  |  | (25,861 | )
Financing activities: |  |  |  |  |  |
Proceeds from equity financing, net |  |  | — |  |  |  | 15,104 |
Proceeds from long-term debt |  |  | 1,110 |  |  |  | — |
Payment of exit fee costs |  |  | (1,110 | ) |  |  | — |
Proceeds from financed insurance premiums |  |  | 333 |  |  |  | 385 |
Repayment of financed insurance premiums |  |  | (150 | ) |  |  | (572 | )
Proceeds from exercise of stock options |  |  | 49 |  |  |  | 4 |
Proceeds from issuance of common stock under employee stock purchase plan |  |  | 56 |  |  |  | 81 |
Payment of debt issuance costs |  |  | (100 | ) |  |  | (25 | )
Cash provided by financing activities |  |  | 188 |  |  |  | 14,977 |
Change in cash and cash equivalents |  |  | (504 | ) |  |  | (22,339 | )
Cash and cash equivalents at beginning of period |  |  | 3,708 |  |  |  | 28,484 |
Cash and cash equivalents at end of period |  | $ | 3,204 |  |  | $ | 6,145 |
Supplemental cash flow disclosures: |  |  |  |  |  |
Income taxes paid |  | $ | 44 |  |  | $ | 41 |
Interest paid, net of amounts capitalized |  | $ | 1,098 |  |  | $ | 1,178 |
Offering costs included in accounts payable and accrued liabilities |  | $ | — |  |  | $ | 18 |
Capitalized property, plant, and equipment included in accounts payable and accrued liabilities |  | $ | 93 |  |  | $ | 90 |
Issuance of common stock warrants |  | $ | — |  |  | $ | 132 |
Recognition of operating right-of-use lease asset |  | $ | 564 |  |  | $ | 1,293 |
Recognition of operating lease liabilities |  | $ | 564 |  |  | $ | 1,306 |

The accompanying notes are an integral part of these condensed financial statements.

9

ALPHA TEKNOVA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Nature of th e Business

Teknova produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our product offerings include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions, with catalog and custom, made-to-order products.

Teknova manufactures its products at its Hollister, California, headquarters and stocks inventory of raw materials, components, and finished goods at that location. The Company ships products directly from its warehouse in Hollister to its customers and distributors.

Note 2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Accounting, Presentation and Use of Estimates

The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with such rules and regulations.

The unaudited condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2024, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the results for the interim periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results may differ from those estimates.

These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the related notes thereto as of and for the year ended December 31, 2024, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 7, 2025 (the 2024 Annual Report on Form 10-K). Refer to “Notes to Financial Statements—Note 2. Summary of Significant Accounting Policies,” within the 2024 Annual Report on Form 10-K for a full list of the Company’s significant accounting policies. The information in those notes has not changed except as a result of normal adjustments in the interim periods.

Reduction in Workforce

On January 11, 2024, the Company carried out a reduction in workforce of approximately 35 positions, aimed at reducing operating expenses. The Company incurred $1.3 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2024, in general and administrative expenses.

Accounting Pronouncements Not Yet Adopted

In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disclosure in the rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciliation items in some categories if the items meet a quantitative threshold. The guidance also requires disclosure of income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. The guidance is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of this standard on the Company’s disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard is

10

effective for annual reporting periods beginning after December 15, 2026, and requires prospective application with the option to apply it retrospectively. The Company is currently evaluating the impact of this standard on the Company’s disclosures.

In July 2025, the FASB issued ASU 2025-05, amending Accounting Standards Codification (ASC) 326, Financial Instruments-Credit Losses, to provide an optional practical expedient when applying the guidance related to the estimation of expected credit losses for current accounts receivable and current contract assets resulting from transactions arising from contracts with customers. Under this practical expedient, entities may elect to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. The guidance is effective for fiscal years beginning after December 15, 2025, and interim reporting periods, with early adoption permitted. The Company is currently evaluating the impact of this standard on the Company’s financial statements.

In September 2025, the FASB issued ASU 2025-06, that clarifies and modernizes the accounting for costs related to internal-use software in ASC 350-40, Intangibles-Goodwill and Other-Internal-Use Software. The guidance removes all references to project stages in ASC 350-40 and clarifies the threshold entities apply to begin capitalizing costs. Additionally, the guidance specifies disclosure requirements for capitalized software costs accounted for under ASC 350-40, regardless of how those costs are presented in the financial statements. The guidance is effective for fiscal years beginning after December 15, 2027, and interim reporting periods, with early adoption permitted. The Company is currently evaluating the impact of this standard on the Company’s financial statements.

Note 3. Segment Reporting

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. Teknova’s CODM is its Chief Executive Officer, currently Stephen Gunstream. Teknova derives revenue primarily in the United States through manufacture and sale of critical reagents. Teknova has determined that it operates in one reporting unit, one operating segment, and one reportable segment, as the CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.

The CODM assesses performance and decides how to allocate resources and make operating decisions based on net loss that is reported on the statement of operations. Net loss is also used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheet as total assets. Revenues, expenses, and assets requiring disclosure in accordance with ASC 280, Segment Reporting, are also included in the accompanying financial statements. See the statements of operations for the three and nine months ended September 30, 2025 and 2024 and the balance sheets as of September 30, 2025 and December 31, 2024, for details.

Note 4. Revenue Recognition

Teknova recognizes revenue from the sale of manufactured products and services when the Company transfers control of promised goods or services to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Control is transferred when the customer has the ability to direct the use of and obtain benefits from the goods or services. The majority of the Company’s sales agreements contain performance obligations satisfied at a point in time when control is transferred to the customer.

Teknova’s revenue, disaggregated by product category, was as follows (in thousands):

|  | For the Three Months Ended September 30, |  |  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Lab Essentials |  | $ | 8,308 |  |  | $ | 7,161 |  |  | $ | 24,217 |  |  | $ | 22,065 |
Clinical Solutions |  |  | 1,706 |  |  |  | 1,964 |  |  |  | 4,928 |  |  |  | 5,247 |
Other |  |  | 440 |  |  |  | 451 |  |  |  | 1,391 |  |  |  | 1,168 |
Total revenue |  | $ | 10,454 |  |  | $ | 9,576 |  |  | $ | 30,536 |  |  | $ | 28,480 |

Teknova’s revenue, disaggregated by geographic region, was as follows (in thousands):

|  | For the Three Months Ended September 30, |  |  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
United States |  | $ | 9,832 |  |  | $ | 9,057 |  |  | $ | 28,881 |  |  | $ | 27,155 |
International |  |  | 622 |  |  |  | 519 |  |  |  | 1,655 |  |  |  | 1,325 |
Total revenue |  | $ | 10,454 |  |  | $ | 9,576 |  |  | $ | 30,536 |  |  | $ | 28,480 |

11

Note 5. Concentrations of Risk

Customers

Customers that accounted for 10% or more of the Company’s revenues and outstanding balance of accounts receivable were as follows:

|  | For the Three Months Ended September 30, |  | For the Nine Months Ended September 30, |  | As of |  | As of
|  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | September 30, 2025 |  | December 31, 2024
Distributor customer A |  | 24% |  | 19% |  | 23% |  | 18% |  | 20% |  | 17%

The Company’s customers that are distributors, as opposed to direct customers, represent highly diversified customer bases.

Suppliers

Suppliers that accounted for 10% or more of the Company’s inventory purchases and outstanding balance of accounts payable were as follows:

|  | For the Three Months Ended September 30, |  | For the Nine Months Ended September 30, |  | As of |  | As of
|  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | September 30, 2025 |  | December 31, 2024
Distributor supplier A |  | 32% |  | 37% |  | 30% |  | 37% |  | 23% |  | 18%
Direct supplier A |  | 20% |  | * |  | 22% |  | * |  | * |  | *
Direct supplier B |  | * |  | * |  | 10% |  | * |  | * |  | *
Direct supplier C |  | 23% |  | 10% |  | 12% |  | 12% |  | * |  | *

* Represents less than 10%.

The Company’s suppliers that are distributors, as opposed to direct suppliers, represent highly diversified supplier bases.

Note 6. Short-term Held-to-Maturity Investments

The Company invests excess cash balances in short-term U.S. Treasuries. Investments are classified based on the facts and circumstances present at the time of purchase. The appropriateness of that classification is subsequently reassessed at each reporting date. As of September 30, 2025, the Company has both the ability and intention to hold these investments until maturity and therefore has classified these investments as held-to-maturity and recorded them at amortized cost which approximates fair value and presented them in “Short-term investments, held -to-maturity” on the balance sheet. The fair value of the Company's short-term investments was based on quoted prices in active markets for these investments (Level 1). The income recognized for these investments was recorded within interest income on the statement of operations.

Note 7. Inventories, Net

Inventories consisted of the following (in thousands):

|  | As of September 30, 2025 |  |  | As of December 31, 2024 |
Finished goods, net |  | $ | 4,158 |  |  | $ | 4,672 |
Work in process |  |  | 112 |  |  |  | 24 |
Raw materials, net |  |  | 2,644 |  |  |  | 2,105 |
Total inventories, net |  | $ | 6,914 |  |  | $ | 6,801 |

12

Note 8. Property, Plant, and Equipment, Net

Property, plant, and equipment consisted of the following (in thousands):

|  | As of September 30, 2025 |  |  | As of December 31, 2024 |
Machinery and equipment |  | $ | 30,012 |  |  | $ | 29,765 |
Office furniture and equipment |  |  | 892 |  |  |  | 922 |
Vehicles |  |  | 333 |  |  |  | 340 |
Leasehold improvements |  |  | 24,843 |  |  |  | 24,346 |
|  |  | 56,080 |  |  |  | 55,373 |
Less—Accumulated depreciation |  |  | (16,078 | ) |  |  | (12,244 | )
|  |  | 40,002 |  |  |  | 43,129 |
Construction in progress |  |  | 2,621 |  |  |  | 2,624 |
Total property, plant, and equipment, net |  | $ | 42,623 |  |  | $ | 45,753 |

For the three and nine months ended September 30, 2025, depreciation expense was $1.3 million and $3.9 million, respectively, and for the three and nine months ended September 30, 2024, depreciation expense was $1.4 million and $4.1 million, respectively.

Note 9. Leases

The Company leases office space, warehouse and manufacturing space, and equipment. The Company’s lease agreements have remaining lease terms of one year to 12 years, and some of these leases have renewal and termination options exercisable at the Company’s election. Terms and conditions to extend or terminate such leases are recognized as part of the right-of-use assets and lease liabilities where reasonably certain to be exercised. All of the Company’s leases are operating leases.

The components of lease expense and other information related to leases were as follows (in thousands):

|  | For the Three Months Ended September 30, |  |  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Operating lease expense |  | $ | 685 |  |  | $ | 745 |  |  | $ | 2,053 |  |  | $ | 2,236 |
Variable lease expense |  |  | 113 |  |  |  | 109 |  |  |  | 340 |  |  |  | 326 |
Total lease expense |  | $ | 798 |  |  | $ | 854 |  |  | $ | 2,393 |  |  | $ | 2,562 |

Cash paid for amounts included in the measurement of the lease liabilities was $0.6 million and $1.9 million for the three and nine months ended September 30, 2025, respectively, and cash paid for amounts included in the measurement of the lease liabilities was $0.7 million and $2.1 million for the three and nine months ended September 30, 2024, respectively. The weighted-average discount rate was 5.0% and the weighted-average remaining lease term was 7.4 years as of September 30, 2025.

Maturities of operating lease liabilities at September 30, 2025 were as follows (in thousands):

|  | Amount |
Remainder of 2025 |  | $ | 745 |
2026 |  |  | 2,649 |
2027 |  |  | 2,714 |
2028 |  |  | 2,770 |
2029 |  |  | 2,770 |
Thereafter |  |  | 7,788 |
Total lease payments |  |  | 19,436 |
Less: imputed interest |  |  | (3,533 | )
Present value of lease liabilities |  |  | 15,903 |
Less: current portion |  |  | (1,886 | )
Lease liabilities less current portion |  | $ | 14,017 |

13

Note 10. Intangible Assets, Net

The following is a summary of intangible assets with definite and indefinite lives (in thousands):

|  | Balance at September 30, 2025 |  |  | Balance at December 31, 2024 |
|  | Gross |  |  | Accumulated Amortization |  |  | Net |  |  | Gross |  |  | Accumulated Amortization |  |  | Net |
Definite Lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  | $ | 9,180 |  |  | $ | 7,700 |  |  | $ | 1,480 |  |  | $ | 9,180 |  |  | $ | 6,839 |  |  | $ | 2,341 |
Indefinite Lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tradename |  |  | 10,750 |  |  |  | — |  |  |  | 10,750 |  |  |  | 10,750 |  |  |  | — |  |  |  | 10,750 |
Total intangible assets |  | $ | 19,930 |  |  | $ | 7,700 |  |  | $ | 12,230 |  |  | $ | 19,930 |  |  | $ | 6,839 |  |  | $ | 13,091 |

For each of the three months ended September 30, 2025 and 2024, amortization expense was $0.3 million and for each of the nine months ended September 30, 2025 and 2024, amortization expense was $0.9 million.

As of September 30, 2025, the remaining weighted-average useful life of definite lived intangible assets was 1.3 years. The estimated future amortization expense of intangible assets with definite lives was as follows (in thousands):

|  | Amount |
Remainder of 2025 |  | $ | 287 |
2026 |  |  | 1,148 |
2027 |  |  | 45 |
Estimated future amortization expense of definite-lived intangible assets |  | $ | 1,480 |

Note 11. Accrued Liabilities

Accrued liabilities were comprised of the following (in thousands):

|  | As of September 30, 2025 |  |  | As of December 31, 2024 |
Payroll-related |  | $ | 2,742 |  |  | $ | 3,041 |
Property, plant, and equipment |  |  | 63 |  |  |  | 89 |
Deferred revenue |  |  | 3 |  |  |  | 30 |
Insurance premiums and accrued interest |  |  | 240 |  |  |  | 56 |
Loss contingency accrual |  |  | — |  |  |  | 373 |
Other |  |  | 918 |  |  |  | 952 |
Total current accrued liabilities |  | $ | 3,966 |  |  | $ | 4,541 |

On July 31, 2025, the Company entered into a financing agreement with First Insurance Funding for the financing of the Company's D&O liability insurance and related policies. Under the terms of the financing agreement, the Company will pay a total of $0.5 million in premiums, taxes, and fees, plus interest at an annual percentage rate of 7.49% in eight monthly installment payments that commenced on August 1, 2025. During the three months ended September 30, 2025, the Company made a down payment on the policy of $0.2 million to the insurer and two monthly installments for an aggregate of $0.1 million to First Insurance Funding. As of September 30, 2025, the Company owed $0.2 million for insurance premiums and accrued interest.

Note 12. Long-term Debt, Net

On March 3, 2025, the Company entered into the Second Amended and Restated Credit and Security Agreement (Term Loan) as borrower, with MidCap Financial Trust (MidCap), as agent and lender, and the additional lenders from time to time party thereto (the Second Amended and Restated Term Loan Credit Agreement) and the Second Amended and Restated Credit and Security Agreement (Revolving Loan) as borrower, with MidCap as agent and lender, and the additional lenders from time to time party thereto (the Second Amended and Restated Revolving Loan Credit Agreement, together with the Second Amended and Restated Term Loan Credit Agreement, the Second Amended and Restated Credit Agreement). The Second Amended and Restated Credit Agreement amends and restates the previous Amended and Restated Credit Agreement (as described and defined in our 2024 Annual Report on Form 10-K).

The Second Amended and Restated Credit Agreement provides for a $28.245 million credit facility consisting of a $23.245 million senior secured term loan (Term Loan) and a $5.0 million working capital facility (Revolver). The Term Loan consists of the

14

$12.135 million balance outstanding under the previous term loan, plus an additional $1.110 million related to the exit fee that would otherwise have been due upon closing of the Second and Amended Restated Term Loan Credit Agreement, as well as an additional tranche of $10.0 million that may become available for use in an acquisition, with MidCap’s consent. The maximum loan amount under the Revolver is $5.0 million, with borrowings limited in accordance with a borrowing base calculation, based solely on eligible accounts receivable.

The interest on the Term Loan is based on the forward-looking one-month term Secured Overnight Financing Rate adjusted upward by 0.10% (Term SOFR), plus an applicable margin of 6.45%, subject to a Term SOFR floor of 3.75%. If any advance under the Term Loan is prepaid at any time, a prepayment fee is charged based on the amount being prepaid and an applicable percentage amount, such as 4%, 3%, or 1%, based on the date the prepayment is made. Interest on an outstanding balance under the Revolver is payable monthly in arrears at an annual rate of Term SOFR plus an applicable margin of 4.00%, subject to a Term SOFR floor of 3.75%.

The Second Amended and Restated Credit Agreement includes minimum net revenue requirements that are measured on a trailing twelve-month basis and a minimum cash requirement throughout the term of the Second Amended and Restated Credit Agreement. For example, the Company’s minimum net revenue requirement for the twelve months ending December 31, 2025, is $39.0 million. The minimum cash requirement is $8.0 million, which includes cash and cash equivalents as well as short-term investments in U.S. Treasuries, under the terms of the Second Amended and Restated Credit Agreement.

The maturity date of the Second Amended and Restated Credit Agreement is March 1, 2030, with principal repayments beginning on April 1, 2028. On the date of termination of the Term Loan or the date on which the obligations under the Term Loan become due and payable in full, the Company will pay an exit fee in an amount equal to 5.0% of the total aggregate principal amount of term loans made pursuant to the Second Amended and Restated Term Loan Credit Agreement as of such date.

Long-term debt, net consisted of the following (in thousands):

|  | As of September 30, 2025 |  |  | As of December 31, 2024 |
Long-term debt |  | $ | 13,245 |  |  | $ | 12,135 |
Cumulative accretion of exit fee |  |  | 70 |  |  |  | 1,544 |
Unamortized debt discount and debt issuance costs |  |  | (239 | ) |  |  | (191 | )
Total debt |  |  | 13,076 |  |  |  | 13,488 |
Less: current portion |  |  | — |  |  |  | (4,045 | )
Long-term debt, net |  | $ | 13,076 |  |  | $ | 9,443 |

At September 30, 2025, the scheduled maturities of the Company’s debt obligations were as follows (in thousands):

|  | Amount |
Remainder of 2025 |  | $ | — |
2026 |  |  | — |
2027 |  |  | — |
2028 |  |  | 5,519 |
2029 |  |  | 6,623 |
Thereafter |  |  | 1,103 |
Total |  | $ | 13,245 |

As of September 30, 2025, the fair value of the Company’s debt approximated its carrying value. The fair value of the Company’s debt was based on observable market inputs (Level 2).

15

Note 13. Stock-Based Compensation

Equity Incentive Plans

The Company maintains a stock incentive plan that permits the granting of incentive stock options or nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other stock-based awards. The equity-based awards for employees generally vest over a four-year period. For initial equity-based awards granted to employees, the first vest is generally a one-year cliff vest, followed by monthly vesting for the final three years. Th ereafter, annual equity-based awards granted to employees typically vest monthly over the four-year vest term, except for restricted stock units which vest annually over a four year period. The initial equity-based awards granted to the Company’s non-employee, independent directors upon appointment to the board of directors vest over a three-year period, with the first vest being a one-year c liff, followed by monthly vesting over the remaining two years. Thereafter, annual equity-based awards granted to the Company’s non-employee, independent directors cliff vest after one year from the date of grant.

Stock Options

The following table summarizes the stock option activity for the nine months ended September 30, 2025 (in thousands, except share and per share data):

|  | Number of Shares |  |  | Weighted Average Exercise Price per Share |  |  | Weighted Average Remaining Contractual Term (in years) |  |  | Aggregate Intrinsic Value (in thousands) |
Outstanding at January 1, 2025 |  |  | 3,992,335 |  |  | $ | 4.99 |  |  |  | 6.86 |  |  | $ | 19,318 |
Granted |  |  | 1,439,255 |  |  | $ | 7.81 |  |  |  |  |  |  |
Exercised |  |  | (20,677 | ) |  | $ | 2.37 |  |  |  |  |  |  |
Forfeited |  |  | (67,769 | ) |  | $ | 7.64 |  |  |  |  |  |  |
Expired |  |  | (32,536 | ) |  | $ | 10.78 |  |  |  |  |  |  |
Outstanding at September 30, 2025 |  |  | 5,310,608 |  |  | $ | 5.69 |  |  |  | 6.95 |  |  | $ | 16,469 |
Exercisable at September 30, 2025 |  |  | 3,083,268 |  |  | $ | 2.31 |  |  |  | 6.07 |  |  | $ | 12,332 |
Vested and expected to vest at September 30, 2025 |  |  | 5,025,926 |  |  | $ | 3.74 |  |  |  | 7.16 |  |  | $ | 14,836 |

The weighted average assumptions used in the Black-Scholes pricing model for stock options granted during the three and nine months ended September 30, 2025 and 2024, were as follows:

|  | For the Three Months Ended September 30, |  |  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Estimated dividend yield |  |  | - | % |  |  | - | % |  |  | - | % |  |  | - | %
Weighted-average expected stock price volatility |  |  | 36.58 | % |  |  | 36.05 | % |  |  | 36.06 | % |  |  | 35.91 | %
Weighted-average risk-free interest rate |  |  | 4.16 | % |  |  | 3.49 | % |  |  | 4.33 | % |  |  | 4.33 | %
Expected average term of options (in years) |  |  | 6.25 |  |  |  | 6.25 |  |  |  | 6.16 |  |  |  | 6.25 |
Weighted-average fair value of common stock |  | $ | 4.44 |  |  | $ | 4.40 |  |  | $ | 7.81 |  |  | $ | 2.86 |
Weighted-average fair value per option |  | $ | 1.94 |  |  | $ | 1.84 |  |  | $ | 3.39 |  |  | $ | 1.24 |

16

Restricted Stock

The following table summarizes the restricted stock unit activity for the nine months ended September 30, 2025 (in thousands, except share and per share data):

|  | Number of Shares |  |  | Weighted Average Grant Date Fair Value per Share |  |  | Weighted Average Remaining Contractual Term (in years) |  |  | Aggregate Intrinsic Value (in thousands) |
Outstanding at January 1, 2025 |  |  | 127,611 |  |  | $ | 3.47 |  |  |  | 0.84 |  |  | $ | 1,066 |
Granted |  |  | — |  |  | $ | — |  |  |  |  |  |  |
Vested |  |  | (82,538 | ) |  | $ | 2.42 |  |  |  |  |  |  |
Forfeited |  |  | — |  |  | $ | — |  |  |  |  |  |  |
Outstanding at September 30, 2025 |  |  | 45,073 |  |  | $ | 5.41 |  |  |  | 0.91 |  |  | $ | 279 |
Vested and expected to vest at September 30, 2025 |  |  | 45,073 |  |  | $ | 5.41 |  |  |  | 0.91 |  |  | $ | 279 |

Employee Stock Purchase Plan

The Company maintains an employee stock purchase plan (ESPP) that authorizes the issuance of shares of common stock pursuant to purchase rights granted to eligible employees. Unless otherwise determined by the Company’s board of directors, shares of the Company’s common stock will be purchased for the accounts of employees participating in the Company’s ESPP at a price per share equal to the lesser of (i) 85% of the fair market value of a share of the Company’s common stock on the first day of an offering; or (ii) 85% of the fair market value of a share of the Company’s common stock on the date of purchase. Offering periods are generally six months long; offering periods begin on June 1 and December 1 of each year. The Company issued zero and 11,518 shares of common stock under the ESPP during the three and nine months ended September 30, 2025 and zero and 54,314 shares of common stock under the ESPP during the three and nine months ended September 30, 2024.

Repricing of Outstanding and Unexercised Options

In January 2024, the Company’s board of directors approved a one-time repricing of certain previously granted and still outstanding vested and unvested stock option awards held by eligible employees, executive officers, and non-employee directors. As a result, the exercise price for these awards was lowered to $2.97 per share effective September 14, 2025, which was the closing price of the Company’s common stock as reported on the Nasdaq Global Stock Market on March 14, 2024, so long as the holder remained employed by the Company or continued to serve as a member of the board of directors through September 14, 2025, absent earlier trigger events defined in the option repricing plan. No other terms of the stock options were modified, and the stock options continue to vest according to their original vesting schedules and retain their original expiration dates. As a result of the repricing, 1,557,301 vested and unvested stock options outstanding as of September 14, 2025, with original exercise prices ranging from $3.02 to $27.49, were repriced.

The repricing on March 14, 2024, resulted in incremental stock-based compensation expense of $0.9 million, of which $0.5 million related to vested stock option awards and was expensed on the repricing date. The remaining $0.4 million related to unvested stock option awards and is being amortized on a straight-line basis over the weighted-average vesting period of those awards of approximately 2.38 years as of March 14, 2024.

Stock-Based Compensation Expense

Stock-based compensation expense included in the accompanying condensed financial statements was as follows (in thousands):

|  | For the Three Months Ended September 30, |  |  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Cost of sales |  | $ | 29 |  |  | $ | 10 |  |  | $ | 85 |  |  | $ | 89 |
Research and development |  |  | 14 |  |  |  | 18 |  |  |  | 13 |  |  |  | 65 |
Sales and marketing |  |  | 61 |  |  |  | 33 |  |  |  | 166 |  |  |  | 162 |
General and administrative |  |  | 746 |  |  |  | 699 |  |  |  | 2,388 |  |  |  | 2,584 |
Total stock-based compensation expense |  | $ | 850 |  |  | $ | 760 |  |  | $ | 2,652 |  |  | $ | 2,900 |

17

Stock-based compensation expense related to stock options was $0.8 million and $2.5 million for the three and nine months ended September 30, 2025, respectively, and $0.7 million and $2.7 million for the three and nine months ended September 30, 2024, respectively. Unrecognized compensation expense related to stock options was $5.4 million at September 30, 2025, which is expected to be recognized as expense over the weighted-average period of 2.71 years.

Stock-based compensation expense related to restricted stock units was no t significant and $0.1 million for the three and nine months ended September 30, 2025, and $0.1 million and $0.2 million for each of the three and nine months ended September 30, 2024. Unrecognized compensation expense related to restricted stock units was $0.2 million at September 30, 2025, which is expected to be recognized as expense over the weighted-average period of 1.41 years.

Stock-based compensation expense related to the ESPP was not significant for either the three and nine months ended September 30, 2025 and 2024. Total compensation cost related to the ESPP not yet recognized was not significant at September 30, 2025. As of September 30, 2025, an insignificant amount has been withheld on behalf of employees for future purchases under the ESPP.

Note 14. Income Taxes

For the three months ended September 30, 2025, the Company’s income tax expense was $0.1 million, compared to the three months ended September 30, 2024, when the Company recorded minimal income tax benefit. The effective tax rates for the three months ended September 30, 2025 and 2024 were (1.9%) and 0.1%, respectively. The effective tax rates differ from the federal statutory rate primarily due to operating losses not expected to produce an income tax benefit.

For the nine months ended September 30, 2025, the Company’s income tax expense was $0.1 million, compared to the nine months ended September 30, 2024 when the Company recorded $0.1 million income tax benefit. The effective tax rates for the nine months ended September 30, 2025 and 2024 were (1.0)% and 0.2%, respectively. The effective tax rates differ from the federal statutory rate primarily due to operating losses not expected to produce an income tax benefit.

The Company had insignificant unrecognized tax benefits as of September 30, 2025 and 2024. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not expect the balance of unrecognized tax benefits to change significantly over the next twelve months. The Company has not accrued interest or penalties related to uncertain tax positions as of September 30, 2025 or 2024.

On July 4, 2025, the United States enacted into law new tax legislation, the One Big Beautiful Bill Act, (OBBBA). The OBBBA includes significant changes to federal tax law and other regulatory provisions. The adoption of this standard did not have a significant impact on the Company’s financial statements nor is it expected to have a material impact on future periods.

Note 15. Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents to the extent they are dilutive. For purposes of this calculation, stock options, restricted stock units, employee stock purchase rights, and warrants to purchase common stock, are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):

|  | For the Three Months Ended September 30, |  |  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Net loss |  | $ | (4,286 | ) |  | $ | (7,565 | ) |  | $ | (12,501 | ) |  | $ | (21,026 | )
Weighted average shares used in computing net loss per share—basic and diluted |  |  | 53,516,986 |  |  |  | 51,821,395 |  |  |  | 53,462,768 |  |  |  | 44,520,132 |
Net loss per share—basic and diluted |  | $ | (0.08 | ) |  | $ | (0.15 | ) |  | $ | (0.23 | ) |  | $ | (0.47 | )

18

Th e following is a summary of the common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive:

|  | For the Three Months Ended September 30, |  |  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Equity-based compensation |  |  | 5,093,158 |  |  |  | 3,873,226 |  |  |  | 4,842,013 |  |  |  | 3,970,116 |
Warrants to purchase common stock |  |  | — |  |  |  | 125,000 |  |  |  | — |  |  |  | 94,434 |

Note 16. Contingencies

From time to time, we may become involved in lawsuits and other claims arising from our ordinary course of business. The Company regularly evaluates its exposure to threatened or pending litigation and other business contingencies. Because of the uncertainties related to the amount of loss from litigation and other business contingencies, the recording of losses relating to such exposures requires significant judgment about the potential range of outcomes. We establish loss provisions for matters in which losses are probable and can be reasonably estimated. If a loss is not both probable and reasonably estimable, or if an exposure to loss exists in excess of the amount accrued, the Company assesses whether there is at least a reasonable possibility that a loss, or additional loss, may have been incurred. If there is a reasonable possibility that a loss, or additional loss, may have been incurred, the Company will disclose the estimate of the possible loss or range of loss if it is material and an estimate can be made, or disclose that such an estimate cannot be made. The determination as to whether a loss can reasonably be considered to be possible or probable is based on our assessment, together with legal counsel, regarding the ultimate outcome of the matter. As additional information about current or future litigation or other contingencies becomes available, the Company will assess whether adjustments should be made to legal accruals.

In August 2023, a former Teknova employee filed a claim with the California Labor and Workforce Development Agency alleging various causes of action under California’s labor, wage, and hour laws. The plaintiff generally alleged that Teknova did not appropriately calculate and pay meal break premiums and otherwise failed to calculate and pay appropriate overtime wages or bonuses to certain of its California non-exempt employees. On June 6, 2024, a mediation took place, in the course of which Teknova agreed to settle the plaintiff’s claims for $0.4 million (the Settlement). As of December 31, 2024, the Company had therefore accrued its best estimate of potential loss related to a possible settlement of the claims of the former employee and other members of the purported class (similarly situated former or current employees), in the amount of $0.4 million, which was included within “Accrued liabilities” on the balance sheet. In April 2025, the Settlement received final court approval and the Company paid the Settlement amount.

19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and related notes thereto included in Part I, Item I of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes thereto for the year ended December 31, 2024, included in the 2024 Annual Report on Form 10-K (the 2024 Annual Report on Form 10-K) filed on March 7, 2025, with the Securities and Exchange Commission (SEC). For a discussion of factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis and elsewhere in this Quarterly Report on Form 10-Q, you should review the risk factors identified in Part I, Item 1A, Risk Factors, of our 2024 Annual Report on Form 10-K and in Item 1A, Risk Factors, of this Quarterly Report on Form 10-Q.

As in Item 1. of this Quarterly Report on Form 10-Q, in this Item 2, unless the context otherwise requires, the terms “Teknova,” the “Company,” “we,” “us,” and “our” refer to Alpha Teknova, Inc.

Overview

Since our founding in 1996, we have been producing critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our approximately 3,000 customers span the entire continuum of the life sciences market, including leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our Company is built around our knowledge, methods, and know-how in our proprietary manufacturing processes, which are highly adaptable and configurable. These proprietary processes enable us to manufacture and deliver high-quality, custom, made-to-order products with short turnaround times and at scale, across all stages of our customers’ product development, from early research through commercialization.

We have two primary product categories: Lab Essentials and Clinical Solutions. Our products cross all stages of development, from early research through commercialization. We offer three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid cell culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification. Our liquid cell culture media and supplements and molecular biology reagents are available in both of our two primary product categories; pre-poured media plates are available in our Lab Essentials category only.

We are ISO 13485:2016 certified, enabling us to manufacture products for use in diagnostic and therapeutic applications. Our certification allows us to offer solutions across the entire customer product development workflow, supporting our customers’ needs for materials in greater volume and that meet increasingly stringent quality requirements as they scale from research to commercialization.

We manufacture our products at our Hollister, California headquarters and stock inventory of raw materials, components, and finished goods at that campus. We rely on a limited number of suppliers for certain raw materials, and we have no long-term supply arrangements with our suppliers, as we order on a purchase order basis. We ship our products directly from our warehouse in Hollister, California, to our customers and distributors, generally pursuant to purchase orders. We typically recognize revenue when products are shipped.

We generated revenue of $10.5 million during the three months ended September 30, 2025, which represents an increase of $0.9 million compared to revenue of $9.6 million during the three months ended September 30, 2024. For the three months ended September 30, 2025 and 2024, only 5.9% and 5.4%, respectively, of our revenue was generated from customers located outside of the United States. We generated revenue of $30.5 million during the nine months ended September 30, 2025, which represents an increase of $2.1 million compared to revenue of $28.5 million during the nine months ended September 30, 2024. For the nine months ended September 30, 2025 and 2024, only 5.4% and 4.7%, respectively, of our revenue was generated from customers located outside of the United States. Our sales outside of the United States are denominated in U.S. Dollars.

We had an operating loss of $4.0 million during the three months ended September 30, 2025, compared to an operating loss of $7.4 million during the three months ended September 30, 2024. We had an operating loss of $12.4 million during the nine months ended September 30, 2025, compared to an operating loss of $20.5 million during the nine months ended September 30, 2024. While our expenses may fluctuate over the short term, we expect our expenses will increase in future periods, in connection with our ongoing activities as we:

20

•
attract, hire, and retain qualified personnel;
•
invest in processes and infrastructure to improve operating efficiency and expand capacity at our facilities, including the ramp up of our new, state-of-the-art manufacturing, warehouse, and distribution facilities; and
•
build our brand and market and sell our products and services.

Impact of Broader Economic Trends on Our Business

We are closely monitoring economic uncertainty in the U.S. and abroad. General inflation in the U.S. rose in recent years to levels not experienced in recent decades. While the rate of inflation moderated in 2024, general inflation, including rising prices for our raw materials and other inputs, as well as rising salaries and other expenses, can negatively impact our business by increasing our cost of sales and operating expenses. In addition, during early 2024, the U.S. Federal Reserve raised interest rates in response to concerns about inflation, and although the U.S. Federal Reserve lowered interest rates in late 2024 and in September 2025, the direction and timing of future interest rate changes remain uncertain. Inflation, together with increased interest rates, and broader macroeconomic uncertainty, may cause our customers to reduce, delay, or cancel orders for our goods and services, thereby causing a decrease in or change in the timing of sales of our products and services. We cannot predict the impact of future inflation and interest rate changes on the results of our operations. Furthermore, changes to tariff and related international trade policy so far in 2025 create uncertainty about the broader economy and our business. For further information regarding the impact of these economic factors on the Company, please see the risk factors identified in Part I, Item 1A, Risk Factors, of our 2024 Annual Report on Form 10-K.

Results of Operations

Comparison of the Three Months Ended September 30, 2025, and Three Months Ended September 30, 2024

The following tables set forth our results of operations for the three months ended September 30, 2025 and 2024 (dollars in thousands):

|  | For the Three Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Revenue |  | $ | 10,454 |  |  | $ | 9,576 |  |  | $ | 878 |  |  |  | 9.2 | %
Cost of sales |  |  | 7,248 |  |  |  | 9,486 |  |  |  | (2,238 | ) |  |  | (23.6 | )%
Gross profit |  |  | 3,206 |  |  |  | 90 |  |  |  | 3,116 |  |  |  | 3462.2 | %
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 542 |  |  |  | 627 |  |  |  | (85 | ) |  |  | (13.6 | )%
Sales and marketing |  |  | 1,747 |  |  |  | 1,640 |  |  |  | 107 |  |  |  | 6.5 | %
General and administrative |  |  | 4,647 |  |  |  | 4,968 |  |  |  | (321 | ) |  |  | (6.5 | )%
Amortization of intangible assets |  |  | 287 |  |  |  | 287 |  |  |  | — |  |  |  | — |
Total operating expenses |  |  | 7,223 |  |  |  | 7,522 |  |  |  | (299 | ) |  |  | (4.0 | )%
Loss from operations |  |  | (4,017 | ) |  |  | (7,432 | ) |  |  | 3,415 |  |  |  | (45.9 | )%
Other expenses, net |  |  |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  | (190 | ) |  |  | (141 | ) |  |  | (49 | ) |  |  | 34.8 | %
Total other expenses, net |  |  | (190 | ) |  |  | (141 | ) |  |  | (49 | ) |  |  | 34.8 | %
Loss before income taxes |  |  | (4,207 | ) |  |  | (7,573 | ) |  |  | 3,366 |  |  |  | (44.4 | )%
Provision for (benefit from) income taxes |  |  | 79 |  |  |  | (8 | ) |  |  | 87 |  |  |  | (1087.5 | )%
Net loss |  | $ | (4,286 | ) |  | $ | (7,565 | ) |  | $ | 3,279 |  |  |  | (43.3 | )%

Revenue

Our revenue disaggregated by product category for the three months ended September 30, 2025 and 2024, was as follows (dollars in thousands):

|  | For the Three Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Lab Essentials |  | $ | 8,308 |  |  | $ | 7,161 |  |  | $ | 1,147 |  |  |  | 16.0 | %
Clinical Solutions |  |  | 1,706 |  |  |  | 1,964 |  |  |  | (258 | ) |  |  | (13.1 | )%
Other |  |  | 440 |  |  |  | 451 |  |  |  | (11 | ) |  |  | (2.4 | )%
Total revenue |  | $ | 10,454 |  |  | $ | 9,576 |  |  | $ | 878 |  |  |  | 9.2 | %

21

Total revenue was $10.5 million and $9.6 million for the three months ended September 30, 2025 and 2024, respectively.

Lab Essentials revenue was $8.3 million for the three months ended September 30, 2025, an increase of $1.1 million, or 16.0%, compared to $7.2 million for the three months ended September 30, 2024. The increase in Lab Essentials revenue was attributable to higher average revenue per customer and, to a slightly lesser extent, an increased number of customers.

Clinical Solutions revenue was $1.7 million for the three months ended September 30, 2025, a decrease of $0.3 million, or 13.1%, compared to $2.0 million for the three months ended September 30, 2024. The decrease in Clinical Solutions revenue was attributable to lower average revenue per customer, partially offset by an increased number of customers.

Our revenue disaggregated by geographic region, for the three months ended September 30, 2025 and 2024, was as follows (dollars in thousands):

|  | For the Three Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
United States |  | $ | 9,832 |  |  | $ | 9,057 |  |  | $ | 775 |  |  |  | 8.6 | %
International |  |  | 622 |  |  |  | 519 |  |  |  | 103 |  |  |  | 19.8 | %
Total revenue |  | $ | 10,454 |  |  | $ | 9,576 |  |  | $ | 878 |  |  |  | 9.2 | %

Revenue from U.S. sales was $9.8 million and $9.1 million for the three months ended September 30, 2025 and 2024, respectively. Revenue from U.S. sales as a percentage of our total revenue was consistent period over period, representing 94.1% and 94.6% of our total revenue during the three months ended September 30, 2025 and 2024, respectively.

Revenue from international sales was $0.6 million and $0.5 million for the three months ended September 30, 2025 and 2024, respectively. Revenue from international sales as a percentage of our total revenue was also consistent period over period, representing 5.9% and 5.4% of our total revenue during the three months ended September 30, 2025 and 2024, respectively.

Gross profit

Our gross profit for the three months ended September 30, 2025 and 2024, was as follows (dollars in thousands):

|  | For the Three Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Cost of sales |  | $ | 7,248 |  |  | $ | 9,486 |  |  | $ | (2,238 | ) |  |  | (23.6 | )%
Gross profit |  |  | 3,206 |  |  |  | 90 |  |  |  | 3,116 |  |  |  | 3462.2 | %
Gross profit % |  |  | 30.7 | % |  |  | 0.9 | % |  |  |  |  |  |

Gross profit percentage was 30.7% and 0.9% for the three months ended September 30, 2025 and 2024, respectively. The increase was primarily driven by $2.8 million of non-recurring and non-cash charges during the three months ended September 30, 2024 related to the disposal of expired inventory and write down of excess inventory. Excluding those non-recurring and non-cash charges, gross profit would have been $2.9 million and gross profit percentage would have been 29.8%, respectively, in the three months ended September 30, 2024. The improvement in gross profit percentage from 29.8% to 30.7% was driven primarily by higher revenue.

Operating expenses

Our operating expenses for the three months ended September 30, 2025 and 2024, were as follows (dollars in thousands):

|  | For the Three Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Research and development |  | $ | 542 |  |  | $ | 627 |  |  | $ | (85 | ) |  |  | (13.6 | )%
Sales and marketing |  |  | 1,747 |  |  |  | 1,640 |  |  |  | 107 |  |  |  | 6.5 | %
General and administrative |  |  | 4,647 |  |  |  | 4,968 |  |  |  | (321 | ) |  |  | (6.5 | )%
Amortization of intangible assets |  |  | 287 |  |  |  | 287 |  |  |  | — |  |  |  | — |
Total operating expenses |  | $ | 7,223 |  |  | $ | 7,522 |  |  | $ | (299 | ) |  |  | (4.0 | )%

Research and development expenses were consistent at $0.5 million and $0.6 million for the three months ended September 30, 2025 and 2024, respectively.

22

Sales and marketing expenses were consistent at $1.7 million and $1.6 million for the three months ended September 30, 2025 and 2024, respectively.

General and administrative expenses were $4.6 million and $5.0 million for the three months ended September 30, 2025 and 2024, respectively. The decrease was driven by a general net reduction in spending.

Amortization of intangible assets was consistent at $0.3 million for each of the three months ended September 30, 2025 and 2024.

Other expenses, net

Our other expenses, net for the three months ended September 30, 2025 and 2024, were as follows (dollars in thousands):

|  | For the Three Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Interest expense, net |  | $ | (190 | ) |  | $ | (141 | ) |  | $ | (49 | ) |  |  | 34.8 | %
Total other expenses, net |  | $ | (190 | ) |  | $ | (141 | ) |  | $ | (49 | ) |  |  | 34.8 | %

Total other expenses, net was $0.2 million for the three months ended September 30, 2025, compared to $0.1 million for the three months ended September 30, 2024. The increase in total other expense, net was primarily attributable to lower interest income somewhat offset by lower interest expense.

Provision for (benefit from) income taxes

Our provision for (benefit from) income taxes for the three months ended September 30, 2025 and 2024, was as follows (dollars in thousands):

|  | For the Three Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Provision for (benefit from) income taxes |  | $ | 79 |  |  | $ | (8 | ) |  | $ | 87 |  |  |  | (1087.5 | )%
Effective tax rate |  |  | (1.9 | )% |  |  | 0.1 | % |  |  |  |  |  |

Our income taxes were not significant for either the three months ended September 30, 2025 or 2024. The effective tax rates for the three months ended September 30, 2025 and 2024 were (1.9%) and 0.1%, respectively. The effective tax rates differ from the federal statutory rate primarily due to operating losses not expected to produce an income tax benefit.

23

Comparison of the Nine Months Ended September 30, 2025, and Nine Months Ended September 30, 2024

The following tables set forth our results of operations for the nine months ended September 30, 2025 and 2024 (dollars in thousands):

|  | For the Nine Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Revenue |  | $ | 30,536 |  |  | $ | 28,480 |  |  | $ | 2,056 |  |  |  | 7.2 | %
Cost of sales |  |  | 20,339 |  |  |  | 23,377 |  |  |  | (3,038 | ) |  |  | (13.0 | )%
Gross profit |  |  | 10,197 |  |  |  | 5,103 |  |  |  | 5,094 |  |  |  | 99.8 | %
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 1,675 |  |  |  | 2,165 |  |  |  | (490 | ) |  |  | (22.6 | )%
Sales and marketing |  |  | 4,960 |  |  |  | 4,763 |  |  |  | 197 |  |  |  | 4.1 | %
General and administrative |  |  | 15,068 |  |  |  | 17,832 |  |  |  | (2,764 | ) |  |  | (15.5 | )%
Amortization of intangible assets |  |  | 861 |  |  |  | 861 |  |  |  | — |  |  |  | — |
Total operating expenses |  |  | 22,564 |  |  |  | 25,621 |  |  |  | (3,057 | ) |  |  | (11.9 | )%
Loss from operations |  |  | (12,367 | ) |  |  | (20,518 | ) |  |  | 8,151 |  |  |  | (39.7 | )%
Other expenses, net |  |  |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  | (499 | ) |  |  | (558 | ) |  |  | 59 |  |  |  | (10.6 | )%
Other adjustment to loan exit fee |  |  | 485 |  |  |  | — |  |  |  | 485 |  |  |  | 100.0 | %
Total other expenses, net |  |  | (14 | ) |  |  | (558 | ) |  |  | 544 |  |  |  | (97.5 | )%
Loss before income taxes |  |  | (12,381 | ) |  |  | (21,076 | ) |  |  | 8,695 |  |  |  | (41.3 | )%
Provision for (benefit from) income taxes |  |  | 120 |  |  |  | (50 | ) |  |  | 170 |  |  |  | (340.0 | )%
Net loss |  | $ | (12,501 | ) |  | $ | (21,026 | ) |  | $ | 8,525 |  |  |  | (40.5 | )%

Revenue

Our revenue disaggregated by product category for the nine months ended September 30, 2025 and 2024, was as follows (dollars in thousands):

|  | For the Nine Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Lab Essentials |  | $ | 24,217 |  |  | $ | 22,065 |  |  | $ | 2,152 |  |  |  | 9.8 | %
Clinical Solutions |  |  | 4,928 |  |  |  | 5,247 |  |  |  | (319 | ) |  |  | (6.1 | )%
Other |  |  | 1,391 |  |  |  | 1,168 |  |  |  | 223 |  |  |  | 19.1 | %
Total revenue |  | $ | 30,536 |  |  | $ | 28,480 |  |  | $ | 2,056 |  |  |  | 7.2 | %

Total revenue was $30.5 million and $28.5 million for the nine months ended September 30, 2025 and 2024, respectively.

Lab Essentials revenue was $24.2 million for the nine months ended September 30, 2025, an increase of $2.2 million, or 9.8%, compared to $22.1 million for the nine months ended September 30, 2024. The increase in Lab Essentials revenue was attributable to an increased number of customers, partially offset by slightly lower average revenue per customer.

Clinical Solutions revenue was $4.9 million for the nine months ended September 30, 2025, a decrease of $0.3 million, or 6.1%, compared to $5.2 million for the nine months ended September 30, 2024. The decrease in Clinical Solutions revenue was attributable to lower average revenue per customer, partially offset by an increased number of customers.

Our revenue disaggregated by geographic region, for the nine months ended September 30, 2025 and 2024, was as follows (dollars in thousands):

|  | For the Nine Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
United States |  | $ | 28,881 |  |  | $ | 27,155 |  |  | $ | 1,726 |  |  |  | 6.4 | %
International |  |  | 1,655 |  |  |  | 1,325 |  |  |  | 330 |  |  |  | 24.9 | %
Total revenue |  | $ | 30,536 |  |  | $ | 28,480 |  |  | $ | 2,056 |  |  |  | 7.2 | %

24

Revenue from U.S. sales was $28.9 million and $27.2 million for the nine months ended September 30, 2025 and 2024, respectively. Revenue from U.S. sales as a percentage of our total revenue was consistent period over period, representing 94.6% and 95.3% of our total revenue during the nine months ended September 30, 2025 and 2024, respectively.

Revenue from international sales was $1.7 million and $1.3 million for the nine months ended September 30, 2025 and 2024, respectively. Revenue from international sales as a percentage of our total revenue was also consistent period over period, representing 5.4% and 4.7% of our total revenue during the nine months ended September 30, 2025 and 2024, respectively.

Gross profit

Our gross profit for the nine months ended September 30, 2025 and 2024, was as follows (dollars in thousands):

|  | For the Nine Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Cost of sales |  | $ | 20,339 |  |  | $ | 23,377 |  |  | $ | (3,038 | ) |  |  | (13.0 | )%
Gross profit |  |  | 10,197 |  |  |  | 5,103 |  |  |  | 5,094 |  |  |  | 99.8 | %
Gross profit % |  |  | 33.4 | % |  |  | 17.9 | % |  |  |  |  |  |

Gross profit percentage was 33.4% and 17.9% for the nine months ended September 30, 2025 and 2024, respectively. The increase was primarily driven by $2.8 million of non-recurring and non-cash charges during the nine months ended September 30, 2024 related to the disposal of expired inventory and write down of excess inventory. Excluding those non-recurring and non-cash charges, gross profit would have been $7.9 million and gross profit percentage would have been 27.6%, respectively, in the nine months ended September 30, 2024. The improvement in gross profit percentage from 27.6% to 33.4% was driven by manufacturing efficiency gains and higher revenue.

Operating expenses

Our operating expenses for the nine months ended September 30, 2025 and 2024, were as follows (dollars in thousands):

|  | For the Nine Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Research and development |  | $ | 1,675 |  |  | $ | 2,165 |  |  | $ | (490 | ) |  |  | (22.6 | )%
Sales and marketing |  |  | 4,960 |  |  |  | 4,763 |  |  |  | 197 |  |  |  | 4.1 | %
General and administrative |  |  | 15,068 |  |  |  | 17,832 |  |  |  | (2,764 | ) |  |  | (15.5 | )%
Amortization of intangible assets |  |  | 861 |  |  |  | 861 |  |  |  | — |  |  |  | — |
Total operating expenses |  | $ | 22,564 |  |  | $ | 25,621 |  |  | $ | (3,057 | ) |  |  | (11.9 | )%

Research and development expenses were $1.7 million and $2.2 million for the nine months ended September 30, 2025 and 2024, respectively. The decrease was primarily driven by lower salaries and wages resulting from the reduction in workforce that was completed early during the three months ended March 31, 2024.

Sales and marketing expenses were $5.0 million and $4.8 million for the nine months ended September 30, 2025 and 2024, respectively. The increase was primarily driven by higher marketing costs during the nine months ended September 30, 2025, partially offset by lower salaries and wages resulting from the reduction in workforce that occurred during the three months ended March 31, 2024.

General and administrative expenses were $15.1 million and $17.8 million for the nine months ended September 30, 2025 and 2024, respectively. Excluding the one-time, non-recurring charges related to the reduction in workforce of $1.3 million and $0.1 million related to the increase of our loss contingency for the nine months ended September 30, 2024, general and administrative expenses decreased $1.4 million. The decrease was driven by reduced spend, primarily on facility costs, insurance, freight, and professional fees as well as lower stock-based compensation expense due to one-time costs incurred in connection with the repricing that occurred during the three months ended March 31, 2024. See “Notes to Financial Statements—Note 13. Stock-Based Compensation” for a more detailed discussion of the stock option repricing.

Amortization of intangible assets was consistent at $0.9 million for each of the nine months ended September 30, 2025 and 2024.

25

Other expenses, net

Our other expenses, net for the nine months ended September 30, 2025 and 2024, were as follows (dollars in thousands):

|  | For the Nine Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Interest expense, net |  | $ | (499 | ) |  | $ | (558 | ) |  | $ | 59 |  |  |  | (10.6 | )%
Other adjustment to loan exit fee |  |  | 485 |  |  |  | — |  |  |  | 485 |  |  |  | 100.0 | %
Total other expenses, net |  | $ | (14 | ) |  | $ | (558 | ) |  | $ | 544 |  |  |  | (97.5 | )%

Total other expenses, net were not significant for the nine months ended September 30, 2025, compared to $0.6 million for the nine months ended September 30, 2024. The decrease in total other expense, net was primarily attributable to a $0.5 million adjustment recognized on the exit fee concurrent with the refinancing of our credit agreement during the three months ended March 31, 2025 coupled with lower interest income, somewhat offset by lower interest expense.

Provision for (benefit from) income taxes

Our provision for (benefit from) income taxes for the nine months ended September 30, 2025 and 2024, was as follows (dollars in thousands):

|  | For the Nine Months Ended September 30, |  |  |  |  |  |  |
|  | 2025 |  |  | 2024 |  |  | $ Change |  |  | % Change |
Provision for (benefit from) income taxes |  | $ | 120 |  |  | $ | (50 | ) |  | $ | 170 |  |  |  | (340.0 | )%
Effective tax rate |  |  | (1.0 | )% |  |  | 0.2 | % |  |  |  |  |  |

Our income taxes were not significant for either the nine months ended September 30, 2025 or 2024. The effective tax rates for the nine months ended September 30, 2025 and 2024 were (1.0)% and 0.2% respectively. The effective tax rates differ from the federal statutory rate primarily due to operating losses not expected to produce an income tax benefit.

Liquidity and Capital Resources

The primary sources of financing for our operations are our (i) registered direct offering and concurrent private placement completed in September 2023 (collectively, the September 2023 Offerings), which resulted in aggregate gross proceeds of $22.9 million before deducting offering expenses of $0.4 million and the prepayment of $10.0 million of the Term Loan , and (ii) private placement completed in July 2024 (the July 2024 Offering), which resulted in aggregate gross proceeds of $15.4 million before deducting offering expenses of $0.2 million.

Our principal liquidity requirements are to fund our operations and capital expenditures. As of September 30, 2025, we had $29.6 million in net working capital, which included $22.1 million in cash and cash equivalents and short-term investments. Our material cash requirements from known contractual obligations and commitments relate primarily to operating leases for our office, manufacturing, warehouse, and distribution facilities at September 30, 2025. See “Notes to Financial Statements—Note 9. Leases,” for a discussion of our lease obligations reflected on our balance sheet.

In addition to our existing cash and cash equivalents and short-term investments, our principal source of liquidity is our credit facility. On March 3, 2025, we entered into the Second Amended and Restated Credit Agreement with MidCap Financial (Midcap) Trust which provides for loan commitments in an aggregate amount of up to $28.245 million consisting of a $23.245 million senior secured term loan (Term Loan) and a $5.0 million working capital facility (Revolver). The Amended Term Loan consists of the $12.135 million balance outstanding under the previous term loan, plus an additional $1.110 million related to the exit fee that would otherwise have been due upon closing of the Second and Amended Restated Term Loan Credit Agreement, as well as an additional tranche of $10.0 million that may become available for use in an acquisition, with MidCap’s consent. The Second Amended and Restated Credit Agreement includes minimum net revenue requirements that are measured on a trailing twelve-month basis and a minimum cash requirement which is constant throughout the term of the agreement. For example, our minimum net revenue requirement for the twelve months ending December 31, 2025, is $39.0 million. The minimum cash requirement is $8.0 million, which includes cash and cash equivalents as well as short-term investments in U.S. Treasuries. See “Notes to Financial Statements—Note 12. Long-term Debt, Net” for a more detailed discussion of the material terms of our Second Amended and Restated Credit Agreement.

26

On July 10, 2025, we filed a “shelf” registration statement on Form S-3 (Reg. No. 333-288613) with the SEC, which was declared effective on July 16, 2025. This shelf registration statement, which includes a base prospectus, allows us at any time to offer any combination of securities described in the prospectus in one or more offerings for our own account in an aggregate amount up to $225 million. The Form S-3 is intended to provide us flexibility to conduct registered sales of our securities, subject to market conditions and our future capital needs. The terms of any future offering under the shelf registration statement will be established at the time of such offering and will be described in a prospectus supplement filed with the SEC prior to the completion of any such offering.

The following table sets forth, for the periods indicated, net cash flows used in operating activities, provided by (used in) investing activities, and provided by financing activities (in thousands):

|  | For the Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |
Net cash used in operating activities |  | $ | (8,184 | ) |  | $ | (11,455 | )
Net cash provided by (used in) investing activities |  |  | 7,492 |  |  |  | (25,861 | )
Net cash provided by financing activities |  |  | 188 |  |  |  | 14,977 |
Net decrease in cash and cash equivalents |  | $ | (504 | ) |  | $ | (22,339 | )

Operating Activities

Net cash used in operating activities consists primarily of net loss adjusted for certain non-cash items (including depreciation and amortization, bad debt expense, deferred taxes, loss on disposal of property, plant, and equipment, inventory reserve, amortization of debt issuance costs, and stock-based compensation expense), and the effect of changes in working capital and other activities.

Net cash used in operating activities was $8.2 million for the nine months ended September 30, 2025, which primarily consisted of net loss of $12.5 million plus net adjustments for non-cash charges of $8.5 million, offset by net changes in operating assets and liabilities of $4.2 million. The primary non-cash adjustments to net loss included $4.8 million of depreciation and amortization, $2.7 million of stock-based compensation, and a $1.7 million provision for inventory, partially offset amortization of the discount on short-term investments of $0.5 million, and an adjustment to the loan exit fee of $0.5 million. The main drivers of the changes in operating assets and liabilities were a $1.8 million increase in inventories, a $1.5 million increase in prepaid expenses and other current assets, a $0.9 million increase in accounts receivable, and a $0.4 million decrease in accrued liabilities, partially offset by a $0.2 million increase in accounts payable.

Net cash used in operating activities was $11.5 million for the nine months ended September 30, 2024, which primarily consisted of net loss of $21.0 million plus net adjustments for non-cash charges of $12.4 million, offset by net changes in operating assets and liabilities of $2.9 million. The primary non-cash adjustments to net loss included $4.9 million of depreciation and amortization, a $4.2 million provision for inventory, $2.9 million of stock-based compensation, and $0.3 million of amortization of debt financing costs. The main drivers of the changes in operating assets and liabilities were a $0.9 million increase in prepaid and other current assets, a $0.7 million decrease in accrued liabilities, a $0.7 million increase in accounts receivable, a $0.4 million decrease in accounts payable, and a $0.3 million increase in inventories, partially offset by a $0.3 million decrease other non-current assets.

Investing Activities

Net cash provided by investing activities was $7.5 million for the nine months ended September 30, 2025, which consisted of maturities of short-term investments of $22.0 million, partially offset by purchases of short-term investments of $13.7 million and purchases of property, plant, and equipment of $0.8 million.

Net cash used in investing activities was $25.9 million for the nine months ended September 30, 2024, which consisted of purchases of short-term investments of $25.4 million and purchases of property, plant, and equipment of $0.6 million, partially offset by proceeds from the sale of certain long-lived assets of $0.1 million.

Financing Activities

Net cash provided by financing activities was $0.2 million for the nine months ended September 30, 2025, which was primarily attributable to proceeds from long-term debt of $1.1 million, proceeds from financed insurance premiums of $0.3 million, and proceeds of $0.1 million from the issuance of common stock under our employee stock purchase plan, largely offset by the payment of exit fee costs of $1.1 million, repayment of financed insurance premiums of $0.2 million, and payment of debt issuance costs of $0.1 million.

27

Net cash provided by financing activities was $15.0 million for the nine months ended September 30, 2024, which was primarily attributable to net proceeds from equity financing of $15.1 million, proceeds from financed insurance premiums of $0.4 million, and proceeds of $0.1 million from the issuance of common stock under our employee stock purchase plan, partially offset by the repayment of financed insurance premiums of $0.6 million.

Critical Accounting Policies and Estimates

For a discussion of our critical accounting estimates, refer to "Management’s Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and the notes to our financial statements in Part II, Item 8 of our 2024 Annual Report on Form 10-K. See also Note 2, Basis of Presentation and Summary of Significant Accounting Policies, to our condensed financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no material changes to our critical accounting estimates since our 2024 Annual Report on Form 10-K.

Emerging Growth Company and Smaller Reporting Company

We qualify as an “emerging growth company” as defined in the JOBS Act. As long as we qualify as an emerging growth company, we may take advantage of certain exemptions from various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to:

•
reduced obligations with respect to financial data, including presenting only two years of audited financial statements;
•
an exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;
•
reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements, and registration statements; and
•
exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements.

In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from adopting new or revised accounting standards, and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies or that have opted out of using such extended transition period, which may make comparison of our financial statements with those of other public companies more difficult. We may take advantage of these reporting exemptions until we no longer qualify as an emerging growth company, or, with respect to adoption of certain new or revised accounting standards, until we irrevocably elect to opt out of using the extended transition period.

Under the JOBS Act, we will remain an emerging growth company until the earliest to occur of:

•
the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more;
•
the last day of our fiscal year following the fifth anniversary of the date of the closing of our initial public offering, which we completed in June 2021 (IPO);
•
the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; and
•
the date on which we are deemed to be a “large accelerated filer” under the Securities Exchange Act of 1934, as amended (the Exchange Act) (i.e., the first day of the fiscal year after we have (i) more than $700.0 million in outstanding common equity held by our non-affiliates, measured each year on the last business day of our most recently completed second fiscal quarter, and (ii) been public for at least 12 months).

We are also a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that (i) the market value of our voting and non-voting common stock held by non-affiliates equals or exceeds $250.0 million measured on the last business day of our most recently completed second fiscal quarter, and our annual revenues are more than $100.0 million during the most recently completed fiscal year or (ii) the market value of our voting and non-voting common stock held by non-affiliates equals or exceeds $700.0 million measured on the last business day of our most recently completed second fiscal quarter.

Recent Accounting Pronouncements

A description of recent accounting pronouncements that may potentially impact our financial position, results of operations, or cash flows is disclosed in Note 2, Basis of Presentation and Summary of Significant Accounting Policies, to our condensed financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

28

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company, as defined in Rule 12b-2 under the Exchange Act for this reporting period and are not required to provide the information required under this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on the evaluation of our disclosure controls and procedures as of September 30, 2025, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

29

PART II—OTH ER INFORMATION

Item 1. Legal Proceedings.

We are not a party to any material legal proceedings at this time. From time to time, we may become involved in various legal proceedings that arise in the ordinary course of business. For example, we may in the future become involved in legal proceedings relating to customers, employees, suppliers, competitors, government agencies, or others. We will evaluate any claims and lawsuits with respect to their potential merits, our potential defenses and counter claims, and the expected effect on us of defending the claims and a potential adverse result. However, the results of any litigation, investigation, or other legal proceedings are inherently unpredictable and potentially expensive. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, damage our reputation, require significant amounts of management time, and divert significant resources. If any legal proceedings were to be determined adversely to us, or we were to enter into a settlement arrangement, we could be exposed to monetary damages or limits on our ability to operate our business, which could have an adverse effect on our business, financial condition, and operating results. Information pertaining to loss contingencies, including those arising out of potential legal liabilities and related matters, are described in Note 16. Contingencies, to our condensed financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

30

Item 1 A. Risk Factors.

While we attempt to identify, manage, and mitigate risks and uncertainties associated with our business to the extent practical under the circumstances, some level of risk and uncertainty will always be present. Item 1A—“Risk Factors” in the 2024 Annual Report on Form 10-K describes some of the risks and uncertainties associated with our business, which we strongly encourage you to review. These risks and uncertainties have the potential to materially affect our business, financial condition, results of operations, cash flows, projected results, and future prospects. Except as set forth below, there have been no material changes in our risk factors from those disclosed in the 2024 Annual Report on Form 10-K.

We have incurred operating losses in the past and may incur losses in the future.

We have incurred operating losses in the past, may incur operating losses in the future and may never achieve or maintain profitability. For the three and nine months ended September 30, 2025, we incurred net losses of $4.3 million and $12.5 million, respectively, and during the three and nine months ended September 30, 2024, we incurred net losses of $7.6 million and $21.0 million, respectively. We have incurred and will continue to incur costs in connection with legal, accounting, and other administrative expenses related to operating as a public company and we expect that our operating expenses will increase modestly with the growth of our business. Since our inception, we have financed our operations primarily through revenue from our products, the sale of our equity securities (including through our June 2021 IPO, September 2023 registered direct offering and private placements, as well as our July 2024 private placements), and debt. While our revenue has generally grown over the last several years, including 2024 compared to 2023, it decreased in 2023 compared to 2022. If our revenue declines or fails to grow at a rate sufficient to offset our operating expenses, we will not be able to achieve and maintain profitability in future periods. We may never be able to generate sufficient revenue to achieve or maintain profitability, and our more recent growth and historical profitability should not be considered predictive of our future performance.

A significant portion of our total outstanding shares of common stock are available for immediate resale and may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. All shares sold in our IPO were freely tradable upon such sale without restriction or further registration under the Securities Act, except for any shares held by our affiliates, as that term is defined under Rule 144 of the Securities Act (Rule 144), including our directors, executive officers, and other affiliates (including Telegraph Hill Partners), which may be sold only in compliance with certain limitations.

As of September 30, 2025, we have 53,524,460 shares of common stock outstanding, the majority of which are held by directors, executive officers, and other affiliates and are subject to volume, manner of sale, and other limitations under Rule 144.

The market price of our stock could decline if the holders of currently restricted shares of common stock sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of our shares of common stock or other securities. In addition, shares of our common stock that are issued pursuant to our equity incentive plans and our Employee Stock Purchase Plan (ESPP) will become eligible for sale in the public market, subject to provisions relating to various vesting agreements, lock-up agreements, and Rule 144, as applicable.

As of September 30, 2025, there were 308,449, 1,330,272 and 3,716,960 shares of common stock reserved for issuance pursuant to outstanding stock option awards under the 2016 Stock Plan, as amended (2016 Plan), the 2020 Equity Incentive Plan, as amended (2020 Plan) and the 2021 Equity Incentive Plan (2021 Plan), respectively. In addition, the 2021 Plan and the ESPP provide for annual automatic increases in the number of shares reserved thereunder. As of January 1, 2025, a total of 6,963,260 and 1,207,030 shares of common stock were available and have been reserved for future issuance under the 2021 Plan and our ESPP, respectively. In the future, we may also issue our securities in connection with investments or acquisitions. The amount of shares of our common stock issued in connection with an investment or acquisition could constitute a material portion of our then-outstanding shares of our common stock. Any issuance of additional securities in connection with investments or acquisitions may result in additional dilution to you.

31

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(a)
Unregistered Sales of Equity Securities

None.

(b)
Use of Proceeds from Initial Public Offering of Common Stock

Not applicable.

(c)
Repurchases

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Rule 10b5-1 Trading Plans

None of our officers or directors (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K), during the three months ended September 30, 2025.

Item 6. Exhibits.

Exhibit Number |  | Description
3.1 |  | Amended and Restated Certificate of Incorporation of Alpha Teknova, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 29, 2021).
3.2 |  | Amended and Restated Bylaws of Alpha Teknova, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 29, 2021).
4.1 |  | Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-256795 filed with the SEC on June 21, 2021).
4.2 |  | Investors’ Rights Agreement, dated as of January 14, 2019, by and among Alpha Teknova, Inc., and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-256795) filed with the SEC on June 4, 2021).
10.1 | § | Second Amended and Restated Credit and Security Agreement (Term Loan), dated as of March 3, 2025, by and among Alpha Teknova, Inc. and MidCap Financial Trust, as agent and as a lender, and the additional lenders from time to time party thereto (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed with the SEC on March 4, 2025).
10.2 | § | Second Amended and Restated Credit and Security Agreement (Revolving Loan), dated as of March 3, 2025, by and among Alpha Teknova, Inc. and MidCap Financial Trust, as agent and as a lender, and the additional lenders from time to time party thereto (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed with the SEC on March 4, 2025).
31.1 | * | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 | * | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 | * | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS |  | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH |  | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

32

104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

§ Non-material schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplemental copies of any of the omitted Schedules and exhibits upon request by the SEC.

33

SIG NATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | ALPHA TEKNOVA INC.
Date: November 7, 2025 |  | By: | /s/ STEPHEN GUNSTREAM
|  |  | Stephen Gunstream
|  |  | President and Chief Executive Officer (Principal Executive Officer)
Date: November 7, 2025 |  | By: | /s/ MATTHEW LOWELL
|  |  | Matthew Lowell
|  |  | Chief Financial Officer (Principal Financial Officer)

34